A 51‐year‐old male CML patient with progressive hearing loss, confusion, ataxia, and aphasia during imatinib treatment

A 51-year-old male was diagnosed with chronic phase chronic myeloid leukemia (CML) in May 2005. His Sokal score at diagnosis was 0.95 and his Euro score was 1,363 (both intermediate risk). Cytogenetic examination showed 46XY, t(9;22)(q34;q11.2) in all of 30 metaphases. BCR-ABL PCR was positive for an e14a2 transcript. He was included in the HOVON-51 study (www.hovon.nl) and received two cycles of cytarabine 200 mg/m 2 for 7 days and imatinib 800 mg, q.d., continuously. Swiftly, he attained a complete and durable cytogenetic response (at 3 months after start of treatment) and a major molecular response (0.05% compared with diagnosis) already at 3 months after start of treatment that was maintained at further follow-up. At 12 months after start of treatment, he complained of progressive hearing problems. There was a perceptive and a conductive loss. An magnetic resonance imaging (MRI) scan of the brain did not show any abnormality of the cerebral parenchyma, meninges, or cranial nerves. He was given a hearing aid and middle ear drainage tubes. However, his hearing loss deteriorated so much that he became unable to do his work as a general practitioner. Six months after his hearing loss had started, he developed progressive confusion, ataxia, and word finding disturbances for which he was admitted to the neurology ward in March 2007. He was afebrile and had a normal blood pressure. There was no lymphadenopathy, nor hepatosplenomegaly. On neurological examination, he appeared bradyphrenic and showed reduced attention. There were slight word finding disturbances and some paraphasias. Neck movements were painful in all directions. There was a slight pupillary anisocoria (right > left) and a staggering gait without further neurological abnormalities.

[1]  N. Shaik,et al.  P-glycoprotein and Breast Cancer Resistance Protein Influence Brain Distribution of Dasatinib , 2009, Journal of Pharmacology and Experimental Therapeutics.

[2]  Jos H. Beijnen,et al.  Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment , 2009, Clinical Cancer Research.

[3]  M. Pirmohamed,et al.  Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. , 2008, Blood.

[4]  S. Mustjoki,et al.  Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. , 2008, Blood.

[5]  J. Melo,et al.  Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications , 2008, Clinical Cancer Research.

[6]  O. Haas,et al.  Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy , 2007, European journal of clinical investigation.

[7]  O. Ayyıldız,et al.  Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report , 2007, Journal of Neuro-Oncology.

[8]  S. Kimura,et al.  INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. , 2007, Blood.

[9]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[10]  F. Mandelli,et al.  Sudden blast crisis in patients with Philadelphia chromosome‐positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy , 2006, Cancer.

[11]  J. Reilly,et al.  Extramedullary blast crises in CML patients in complete hematological remission treated with imatinib mesylate. , 2006, Clinical and laboratory haematology.

[12]  H. Kantarjian,et al.  Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate. , 2006, Blood.

[13]  Y. Maeda,et al.  Extramedullary Blast Crisis Derived from 2 Different Clones in the Central Nervous System and Neck during Complete Cytogenetic Remission of Chronic Myelogenous Leukemia Treated with Imatinib Mesylate , 2005, International journal of hematology.

[14]  J. Schellens,et al.  The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. , 2005, Cancer research.

[15]  S. Uppin,et al.  Isolated central nervous system blast crisis in chronic myeloid leukemia , 2004, Hematological oncology.

[16]  Q. Waisfisz,et al.  Secondary imatinib resistance associated with an aberrant bcr-abl fusion gene , 2004, Leukemia.

[17]  J. Ford,et al.  Central Nervous System Failure in Patients with Chronic Myelogenous Leukemia Lymphoid Blast Crisis and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Treated with Imatinib (STI-571) , 2004, Leukemia & lymphoma.

[18]  F. Balis,et al.  Plasma and Cerebrospinal Fluid Pharmacokinetics of Imatinib after Administration to Nonhuman Primates , 2004, Clinical Cancer Research.

[19]  G. Ehninger,et al.  CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid , 2004, Annals of Hematology.

[20]  B. Dörken,et al.  Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588 , 2004, Cancer Chemotherapy and Pharmacology.

[21]  J. Richardson,et al.  The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia. , 2003, Blood.

[22]  Y. Ikeda,et al.  Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome‐positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid , 2002, British journal of haematology.

[23]  W. Poewe,et al.  Low concentrations of STI571 in the cerebrospinal fluid: a case report , 2002, British journal of haematology.

[24]  T. Holyoake,et al.  Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. , 2002, Blood.

[25]  C. Sawyers,et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. , 2001, The New England journal of medicine.